HRP20080359B1 - PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a - Google Patents

PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a

Info

Publication number
HRP20080359B1
HRP20080359B1 HRP20080359AA HRP20080359A HRP20080359B1 HR P20080359 B1 HRP20080359 B1 HR P20080359B1 HR P20080359A A HRP20080359A A HR P20080359AA HR P20080359 A HRP20080359 A HR P20080359A HR P20080359 B1 HRP20080359 B1 HR P20080359B1
Authority
HR
Croatia
Prior art keywords
alkyl
optionally substituted
alkyloxy
amino
nhc
Prior art date
Application number
HRP20080359AA
Other languages
English (en)
Croatian (hr)
Inventor
Bart De Corte
Marc Rene De Jonge
Jan Heeres
Chih Yung Ho
Paul Adriaan Jan Janssen
Robert W. Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Koen Jeanne Alfons Van Aken
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20080359(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20080359A2 publication Critical patent/HRP20080359A2/xx
Publication of HRP20080359B1 publication Critical patent/HRP20080359B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20080359AA 1998-11-10 1999-09-24 PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a HRP20080359B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (2)

Publication Number Publication Date
HRP20080359A2 HRP20080359A2 (en) 2008-12-31
HRP20080359B1 true HRP20080359B1 (hr) 2016-01-01

Family

ID=26805159

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20080359AA HRP20080359B1 (hr) 1998-11-10 1999-09-24 PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
HRP20010161AA HRP20010161B9 (hr) 1998-11-10 1999-09-24 PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20010161AA HRP20010161B9 (hr) 1998-11-10 1999-09-24 PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a

Country Status (41)

Country Link
US (5) US6878717B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1002795B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3635238B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100658489B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1214013C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP1683A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR024227A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE233740T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU762523C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG65103B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI9915552B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2350801C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2008021I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ301367B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69905683T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1002795T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA004049B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05086B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2338760T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR09C0004I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1048817B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20080359B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU227453B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID28376A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL143023A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1002795I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91528I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY121108A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300373I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO318801B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ511116A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11674A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL204427B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1002795E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1002795T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (2) SK287269B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200101306T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI238161B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA70966C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000027825A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200103769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027825A1 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
PL207590B1 (pl) 1999-09-24 2011-01-31 Janssen Pharmaceutica Nv Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
ES2559273T3 (es) 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
CN100339846C (zh) * 2000-11-01 2007-09-26 斯雷普内姆斯·Com公司 对域名数据的状态变化进行实时监测并即时注册的系统及方法
NZ529654A (en) 2001-05-29 2005-12-23 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
DK1438053T3 (da) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
CN100491371C (zh) 2001-11-01 2009-05-27 詹森药业有限公司 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
NZ531855A (en) 2001-11-01 2005-12-23 Janssen Pharmaceutica Nv Amide derivatives as glycogen synthase kinase 3-beta inhibitors
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
NZ534771A (en) 2002-03-13 2006-04-28 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
IL164006A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA04010778A (es) * 2002-05-03 2005-03-07 Janssen Pharmaceutica Nv Microemulsiones polimericas.
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
IL166241A (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases
CN101481356B (zh) 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
HUE038446T2 (hu) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Szekvesztráló alegység és releváns kompozíciók és módszerek
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
US7585861B2 (en) * 2003-02-07 2009-09-08 Janssen Pharmaceutica, N.V. HIV inhibiting 1,2,4-triazines
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
ATE433447T1 (de) * 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ES2667668T3 (es) * 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2005028479A2 (en) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
JP5213228B2 (ja) 2004-03-02 2013-06-19 ビルコ・ビーブイビーエイ 臨床的カット−オフ値の推測
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
SG156687A1 (en) 2004-07-28 2009-11-26 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
JP5031564B2 (ja) 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
BRPI0516748B8 (pt) * 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas 5-substituídas inibidoras de hiv e composição farmacêutica que as compreende
ATE520672T1 (de) * 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
ES2371923T3 (es) 2004-09-30 2012-01-11 Tibotec Pharmaceuticals 5-heterociclil-pirimidinas que inhiben el vih.
JP5118972B2 (ja) 2004-10-29 2013-01-16 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性二環式ピリミジン誘導体
EP1812069A2 (en) * 2004-11-08 2007-08-01 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and etravirine
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
SI1856135T1 (sl) 2005-01-19 2010-04-30 Rigel Pharmaceuticals Inc Predzdravila 2,4-pirimidindiaminskih spojin in njihove uporabe
JP5190272B2 (ja) * 2005-01-27 2013-04-24 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性２（４−シアノフェニルアミノ）ピリミジン誘導体
NZ561525A (en) 2005-02-16 2010-11-26 Astrazeneca Ab Benzimidazole compounds and analogues, containing a pyrazole ring, for inhibition of Trk activity, affecting cancer
MX2007010051A (es) * 2005-02-18 2007-09-21 Tibotec Pharm Ltd Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
BRPI0609291B1 (pt) * 2005-03-04 2022-02-08 Janssen Sciences Ireland Uc 2-(4-ciano-fenil)-o-hidroxilamina-pirimidinas que inibem hiv, composição farmacêutica que as compreende e processo para a preparação de ambas
MX2007014328A (es) 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
RU2458056C2 (ru) 2005-05-26 2012-08-10 Тиботек Фармасьютикалз Лтд Способ получения 4-(1,6-дигидро-6-оксо-2-пиримидинил)амино-бензонитрила
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007044565A2 (en) * 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
MX2008005398A (es) 2005-10-28 2008-09-24 Astrazeneca Ab Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
CN101370790B (zh) 2006-01-19 2015-10-21 詹森药业有限公司 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
JP5137849B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
RS51191B (sr) 2006-01-19 2010-10-31 Janssen Pharmaceutica N.V. Derivati aminofenila kao novi inhibitori histon deacetilaze
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
WO2007113254A1 (en) 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
MX2008012577A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas sustituidas con 5-(hidroximetileno y aminometileno) que inhiben el virus de inmunodeficiencia humana.
US8623887B2 (en) 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
CA2651665C (en) * 2006-06-06 2010-04-27 Tibotec Pharmaceuticals Ltd. Process for preparing spray dried formulations of tmc125
RU2445077C2 (ru) 2006-06-19 2012-03-20 АЛФАРМА, Инк. Фармацевтические композиции
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
EP2104491B1 (en) 2006-12-06 2017-02-22 Janssen Sciences Ireland UC Hydrobromide salt of an anti-hiv compound
KR20090094073A (ko) * 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
CA2674185C (en) 2006-12-29 2017-02-28 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5,6-substituted pyrimidines
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2009079521A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
WO2010038081A2 (en) * 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
CN102369009B (zh) 2009-03-30 2014-04-30 泰博特克药品公司 依曲韦林和烟酰胺的共晶体
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
ES2527103T3 (es) * 2009-06-22 2015-01-20 Emcure Pharmaceuticals Limited Procedimiento para la síntesis de etravirina
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
SI2576541T1 (sl) 2010-06-04 2016-07-29 F. Hoffmann-La Roche Ag Aminopirimidinski derivati kot modulatorji lrrk2
EP2584901A4 (en) 2010-06-28 2013-10-09 Hetero Research Foundation PROCESS FOR PREPARING THE INTERMEDIATE OF STRAIN AND STRAIN OF POLYMORPHS
AU2011289604C1 (en) 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
NZ609957A (en) 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
TW201302733A (zh) 2010-11-10 2013-01-16 Hoffmann La Roche 作為ｌｒｒｋ２調節劑之吡唑胺基嘧啶衍生物
WO2012147104A1 (en) 2011-04-26 2012-11-01 Mylan Laboratories Ltd Novel process for the preparation of etravirine
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
JP5993010B2 (ja) 2011-08-23 2016-09-14 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリミド−ピリダジノン化合物及びその使用
US20130123498A1 (en) 2011-10-19 2013-05-16 Maja Sepelj MAJER Process for the preparation of etravirine and intermediates in the synthesis thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
CN108658873B (zh) 2012-03-15 2021-09-14 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的固体形式
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AU2013362755B2 (en) 2012-12-21 2018-09-13 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
ES2995737T3 (en) 2015-01-06 2025-02-11 Arena Pharm Inc Compound for use in treating conditions related to the s1p1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
CN110809471A (zh) 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041512A1 (en) * 1997-03-14 1998-09-24 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
EP0945443A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4694009A (en) * 1984-06-25 1987-09-15 Ciba-Geigy Corporation Pesticidal compositions
DE68918804T2 (de) 1988-03-31 1995-02-23 Mitsubishi Chem Ind Acyclische 6-substituierte pyrimidin nukleosid-abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten.
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ322907A (en) 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
AU748087B2 (en) 1998-02-17 2002-05-30 Tularik Inc. Anti-viral pyrimidine derivatives
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP0945442A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
WO2000027825A1 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
ES2559273T3 (es) * 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041512A1 (en) * 1997-03-14 1998-09-24 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
EP0945443A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives

Also Published As

Publication number Publication date
BRPI9915552B8 (pt) 2021-05-25
US6878717B2 (en) 2005-04-12
LU91528I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-02
AU762523B2 (en) 2003-06-26
DE122009000003I1 (de) 2009-05-20
DE69905683T2 (de) 2004-03-18
BG105418A (en) 2001-11-30
ID28376A (id) 2001-05-17
HUP0104177A3 (en) 2003-01-28
CY2008021I2 (el) 2010-07-28
HRP20010161B1 (en) 2009-03-31
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
HRP20080359A2 (en) 2008-12-31
EA200100536A1 (ru) 2002-02-28
ES2193664T3 (es) 2003-11-01
HRP20010161B9 (hr) 2014-10-24
CA2350801A1 (en) 2000-05-18
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
HU227453B1 (en) 2011-06-28
NO2009003I2 (no) 2010-06-07
EP1002795B1 (en) 2003-03-05
TR200101306T2 (tr) 2001-10-22
HK1048817B (en) 2010-04-09
US20110263625A1 (en) 2011-10-27
BR9915552B1 (pt) 2013-11-19
TWI238161B (en) 2005-08-21
NL300373I2 (nl) 2009-04-01
PL347586A1 (en) 2002-04-08
HU230394B1 (hu) 2016-04-28
NO20011696D0 (no) 2001-04-04
EE200100252A (et) 2002-10-15
NO2009003I1 (no) 2009-03-09
ZA200103769B (en) 2002-08-12
JP3635238B2 (ja) 2005-04-06
US8530655B2 (en) 2013-09-10
EP1270560A1 (en) 2003-01-02
CA2350801C (en) 2008-05-20
AU2011200708A1 (en) 2011-03-10
CZ301367B6 (cs) 2010-02-03
HK1025330A1 (en) 2000-11-10
ATE455107T1 (de) 2010-01-15
CN1214013C (zh) 2005-08-10
BR9915552A (pt) 2001-08-14
SK287269B6 (sk) 2010-05-07
SK6032001A3 (en) 2002-01-07
LU91528I2 (fr) 2009-04-20
AR024227A1 (es) 2002-09-25
KR100658489B1 (ko) 2006-12-18
OA11674A (en) 2005-01-12
WO2000027825A1 (en) 2000-05-18
BG65103B1 (bg) 2007-02-28
FR09C0004I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-02-27
FR09C0004I2 (fr) 2010-06-11
SI1002795T1 (en) 2003-10-31
IL169949A (en) 2011-02-28
EP1270560B1 (en) 2010-01-13
AU762523C (en) 2004-02-12
LTPA2008016I1 (lt) 2021-04-26
CN1322198A (zh) 2001-11-14
CY2008021I1 (el) 2010-07-28
AP1683A (en) 2006-11-29
UA70966C2 (uk) 2004-11-15
HK1048817A1 (en) 2003-04-17
NO318801B1 (no) 2005-05-09
US8003789B2 (en) 2011-08-23
JP2002529456A (ja) 2002-09-10
NZ511116A (en) 2003-08-29
PT1002795E (pt) 2003-07-31
IL143023A0 (en) 2002-04-21
CZ20011533A3 (cs) 2001-10-17
ATE233740T1 (de) 2003-03-15
US20050288278A1 (en) 2005-12-29
US7037917B2 (en) 2006-05-02
HRP20010161A2 (en) 2002-02-28
ES2338760T3 (es) 2010-05-12
MY121108A (en) 2005-12-30
LTC1002795I2 (lt) 2021-06-10
NO20011696L (no) 2001-04-04
DE69941934D1 (de) 2010-03-04
HUP0104177A2 (hu) 2002-03-28
PL204427B1 (pl) 2010-01-29
EE05086B1 (et) 2008-10-15
NO2021015I1 (no) 2021-03-29
EA004049B1 (ru) 2003-12-25
KR20010075235A (ko) 2001-08-09
US20040039005A1 (en) 2004-02-26
NL300373I1 (nl) 2009-03-02
US20080176880A1 (en) 2008-07-24
AU6200899A (en) 2000-05-29
EP1002795A1 (en) 2000-05-24

Similar Documents

Publication Publication Date Title
HRP20080359B1 (hr) PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
AP1610A (en) HIV replication inhibiting pyrimidines.
MY141597A (en) 2,4-disubstituted thiazolyl derivatives
HRP20050688A2 (en) Pyrimidine derivatives for the prevention of hiv infection
TR200002760T2 (tr) HIV engelleyici pirimidin türevleri
CY1109756T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικα αλατα 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2- [μεθυλ(μεθυλσουλφονυλ)αμινο] πυριμιδιν-5-υλ]-(3r,5s)-3,5-διυδροξυεπτ-6-ενοϊκου οξεος
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
YU27697A (sh) Sulfonamidi i njihiova upotreba
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
HRP20040097B1 (hr) 2-amino-4,5-trisupstituirani derivati tiazolila
BR0214876A (pt) Formas de sal de e-2-metóxi-n-(3-(4-(3-metil-piridin-3-ilóxi)-fenilamino)qui nazolin-6-il)-alil)-acetamida, suas preparações e uso dos mesmos contra o câncer
MY129224A (en) 4-phenyl-pyridine derivatives
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
ATE21900T1 (de) Pyrimidinonderivate und diese enthaltende pharmazeutische zusammenstellungen.
CY1105596T1 (el) Παραγωγα 2,4-δισυποκατεστημενης τριαζινης με δραση κατα του hiv
AR038824A1 (es) Composiciones de medicamentos que, junto a agentes colinergicos, contienen compuestos heterociclicos
ATE500231T1 (de) Hiv hemmende pyrimidin derivate
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
FI933064A7 (fi) 2-amino-N-(((4-(aminokarbonyyli)pyrimidin2-yyli)amino)alkyyli)pyrimidin-4-karboksamidijohdannaiset, niiden valmistus ja terapeuttinen käyttö
CY1125571T1 (el) Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv
DOP2004001030A (es) Heterociclos amino de seis eslabones que contienen nitrogeno sustituido como antagonistas del receptor 1 vainilloide para tratamiento del dolor
TH76074A (th) อะมิโน-เฮทเทอโรไซเคิลที่มีหกสมาชิกซึ่งมีไนโตรเจนที่ถูกแทนที่ซึ่งเป็นวานิลลอยด์-1 รีเซพเตอร์ แอนทาโกนิสต์สำหรับการทรีตอาการปวด
RU92016623A (ru) Новые противовирусные тетрагидроимидазо-[1,4]-бензодиазепин-2(ти)-оны
UA81654C2 (ru) Пиримидины и триазины, которые ингибируют репликацию вич

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180814

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20190924